Erich A. Leeser

Array ( [id] => 19257986 [patent_doc_number] => 12018028 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-25 [patent_title] => 5-substituted aminopyrazino[2',1':2,3]imidazo[4,5-c][2,7]naphthyridine compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/388620 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8469 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065630 [patent_doc_number] => 20240100056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => METHODS OF TREATING CANCER WITH AN MTOR INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/506061 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19273220 [patent_doc_number] => 12023327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Methods of treating gastrointestinal stromal tumors [patent_app_type] => utility [patent_app_number] => 18/500730 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 17015 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032411 [patent_doc_number] => 20240082226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS [patent_app_type] => utility [patent_app_number] => 18/500686 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19367350 [patent_doc_number] => 12059410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Methods of treating gastrointestinal stromal tumors [patent_app_type] => utility [patent_app_number] => 18/500549 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 17196 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19273218 [patent_doc_number] => 12023325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Methods of treating gastrointestinal stromal tumors [patent_app_type] => utility [patent_app_number] => 18/500650 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 17219 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19367351 [patent_doc_number] => 12059411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Methods of treating gastrointestinal stromal tumors [patent_app_type] => utility [patent_app_number] => 18/500792 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 17220 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034103 [patent_doc_number] => 20240083918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => IMIDAZOPYRIDAZINE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/385742 [patent_app_country] => US [patent_app_date] => 2023-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020131 [patent_doc_number] => 20240076302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 18/496034 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332544 [patent_doc_number] => 20240246974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/382210 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332544 [patent_doc_number] => 20240246974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/382210 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332544 [patent_doc_number] => 20240246974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/382210 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987720 [patent_doc_number] => 20240059689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => PURINE DERIVATIVES AS ANTICANCER AGENTS [patent_app_type] => utility [patent_app_number] => 18/468385 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 133176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987720 [patent_doc_number] => 20240059689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => PURINE DERIVATIVES AS ANTICANCER AGENTS [patent_app_type] => utility [patent_app_number] => 18/468385 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 133176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043535 [patent_doc_number] => 11932619 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-19 [patent_title] => 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound [patent_app_type] => utility [patent_app_number] => 18/367895 [patent_app_country] => US [patent_app_date] => 2023-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3942 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18367895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18980112 [patent_doc_number] => 11905272 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-20 [patent_title] => 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound [patent_app_type] => utility [patent_app_number] => 18/244972 [patent_app_country] => US [patent_app_date] => 2023-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3963 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081823 [patent_doc_number] => 20240108624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/463865 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081823 [patent_doc_number] => 20240108624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/463865 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842608 [patent_doc_number] => 20230405012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => IRAK4 DEGRADERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/459675 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964151 [patent_doc_number] => 11897901 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-13 [patent_title] => 6-amino-8,9-di(4-methoxyphenyl)-2-oxo-3,9-dihydro-2H-[1,3]thiazolo[5',4':5,6]pyrano[2,3-b]pyridine-7-carbonitrile as anticancer compound [patent_app_type] => utility [patent_app_number] => 18/239258 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3814 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239258 [rel_patent_id] =>[rel_patent_doc_number] =>)